F. J. M. van Kuppeveld

This study identifies the SARS-CoV-2 nucleocapsid protein's N2b domain as inhibiting PKR-mediated integrated stress response and innate immunity by sequestering dsRNA.

This study shows that sialoglycan binding triggers the opening of the spike protein in the human coronavirus HKU1 through allosteric inter-domain cross-talk.

This paper discovers a macrocyclic peptide that inhibits SARS-CoV-2 and related sarbecoviruses by targeting a conserved site in the spike protein, offering a potential broad-spectrum antiviral.

This study uses live-cell imaging to show that antiviral response activation varies in timing and strength based on viral replication dynamics and signaling pathway strength.

This study shows the EMCV Leader protein promotes EV-mediated virus release by inducing secretory autophagy, revealing a new role for non-structural viral proteins in non-lytic release.

This study identifies fluoxetine as an inhibitor of the enterovirus 2C AAA+ ATPase, revealing its mechanism of action through structural and functional analyses.

This paper develops a replicon-based vaccine that prevents SARS-CoV-2 infection and transmission in cats.

RAPPID is a homogeneous immunoassay platform using ratiometric bioluminescent sensors for direct in-sample calibration and quantitative detection of biomarkers.

This paper identifies a human monoclonal antibody, 47D11, that targets a conserved hydrophobic pocket in the SARS-CoV-2 RBD, revealing its structural basis for neutralization and potential therapeutic use.

The paper shows that S and HE proteins co-evolve to balance attachment and release in coronaviruses, with functional interdependence observed in OC43 and HKU1.

The paper presents the cryo-EM structure of HKU1 HE, revealing structural changes due to prolonged human circulation, including a truncated lectin domain and intact esterase domain.

This study shows that high-dose convalescent plasma or monoclonal antibodies protect hamsters from SARS-CoV-2-induced lower respiratory disease, but lower doses are ineffective.

This paper reports a human monoclonal antibody that neutralizes SARS-CoV-2 and SARS-CoV, targeting a shared epitope for potential prevention and treatment of COVID-19.

This study characterizes the c10orf76-PI4KB complex, showing its role in maintaining Golgi PI4P levels and enabling enterovirus replication.

This study identifies ACBD3 as an essential host factor mediating 3A protein interaction with PI4KB, crucial for enterovirus replication.